Status:
COMPLETED
Zosuquidar in Combination With Daunorubicin and Cytarabine in Patients Ages 55-75 With Newly Diagnosed Acute Myeloid Leukemia (AML)
Lead Sponsor:
Kanisa Pharmaceuticals
Conditions:
Leukemia, Myeloid
Eligibility:
All Genders
55-75 years
Phase:
PHASE1
PHASE2
Brief Summary
Chemotherapy drugs use different ways to stop cancer cells from dividing so they stop growing or die. Zosuquidar may help daunorubicin and cytarabine kill more cancer cells by making cancer cells more...
Detailed Description
Purpose: Phase I: To Evaluate the safety of different doses of zosuquidar. Phase II: This study is designed to study the safety and effectiveness of zosuquidar when given with daunorubicin and cyt...
Eligibility Criteria
Inclusion
- Newly diagnosed acute myeloid leukemia
- Ages 55-75 years
Exclusion
- Acute promyelocytic leukemia (FAB M3)
- Patients must not have received prior chemotherapy for AML.
- Prior exposure to anthracycline
- Use of any investigational agent within 4 weeks prior to enrollment into the study
- For Phase II:
- Patients must be P-glycoprotein positive
Key Trial Info
Start Date :
August 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2008
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00129168
Start Date
August 1 2005
End Date
March 1 2008
Last Update
April 1 2008
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.